Louisiana State Employees Retirement System Takes $1 Million Position in LivaNova PLC $LIVN

Louisiana State Employees Retirement System purchased a new stake in shares of LivaNova PLC (NASDAQ:LIVN) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 15,800 shares of the company’s stock, valued at approximately $1,004,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in LivaNova by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after buying an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of LivaNova by 4.6% in the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after acquiring an additional 36,094 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of LivaNova by 10.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock valued at $6,633,000 after acquiring an additional 15,405 shares in the last quarter. Intech Investment Management LLC increased its position in shares of LivaNova by 19.6% during the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after acquiring an additional 7,195 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of LivaNova during the first quarter valued at approximately $130,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Robert W. Baird decreased their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Barclays lifted their target price on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. KeyCorp boosted their price target on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. Finally, Freedom Capital upgraded shares of LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $80.75.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $83.62 on Friday. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The stock has a fifty day simple moving average of $73.95 and a two-hundred day simple moving average of $67.62. LivaNova PLC has a 1-year low of $41.01 and a 1-year high of $83.98. The firm has a market cap of $4.59 billion, a price-to-earnings ratio of 42.88 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. During the same period in the previous year, the company posted $0.88 earnings per share. The business’s revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Analysts anticipate that LivaNova PLC will post 3.73 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.35% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.